Keros Therapeutics, Inc. (KROS) has disclosed a new risk, in the Corporate Activity and Growth category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Keros Therapeutics, Inc. faces significant risks from its corporate restructuring announced in May 2025, which aimed to cut costs by reducing its workforce by 45%. While the company anticipates annual savings of $17 million, these projections are uncertain and could be undermined by unforeseen challenges, potentially impacting its financial health. The restructuring might disrupt operations, lower employee morale, and hinder compliance with legal requirements, posing further risks to its ability to attract and retain essential personnel. Such disruptions could adversely affect the development of KER-065 and ongoing collaborations, threatening the company’s strategic objectives.
The average KROS stock price target is $24.17, implying 80.91% upside potential.
To learn more about Keros Therapeutics, Inc.’s risk factors, click here.